Showing 1951-1960 of 3038 results for "".
- Novartis and Microsoft Announce Collaboration to Transform Medicine with Artificial Intelligencehttps://modernod.com/news/novartis-and-microsoft-announce-collaboration-to-transform-medicine-with-artificial-intelligence/2476932/Novartis announced a step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science partner for this effort, according to a company news release. The new lab aims to bolster Novartis AI capabilities from research through com
- Product Specific J-Code for Omeros’ Omidria is Now in Effecthttps://modernod.com/news/product-specific-j-code-for-omeros-omidria-is-now-in-effect/2476927/Omeros announced that the product specific J-code for Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% is now effective. Omidria is Omeros’ commercial drug marketed for use during cataract surgery to prevent miosis and reduce postoperative pain. The new permanent J-code f
- Novo Nordisk’s Rybelsus Gains FDA Approval as First Oral GLP-1 Receptor Agonist for Type 2 Diabeteshttps://modernod.com/news/novo-nordisks-rybelsus-gains-fda-approval-as-first-oral-glp-1-receptor-agonist-for-type-2-diabetes/2476907/The FDA announced Friday the approval of Novo Nordisk’s Rybelsus (semaglutide) to improve control of blood glucose in adults with type 2 diabetes, along with diet and exercise, making it the first oral GLP-1 receptor agonist cleared in the US. Lisa Yanoff, acting director of the Division of
- Konan Medical’s EyeKinetix Pupillograph is Now Available in the United Stateshttps://modernod.com/news/konan-medicals-eyekinetix-pupillograph-is-now-available-in-the-united-states/2476902/Konan Medical announced that EyeKinetix is FDA listed and now available for sale in the United States. EyeKinetix is Konan’s 2nd generation pupillograph, which is smaller, faster, easier to use and less expensive than its predecessor, RAPDx, a device that brought key pupillary testin
- SightGlass Vision to Present Pivotal Clinical Trial Baseline Data Evaluating Novel Lenses to Control Nearsightedness in Childrenhttps://modernod.com/news/sightglass-vision-to-present-pivotal-clinical-trial-baseline-data-evaluating-novel-lenses-to-control-nearsightedness-in-children/2476876/SightGlass Vision announced that baseline data from CYPRESS, the company’s pivotal trial assessing the safety and efficacy of novel lenses designed to control nearsightedness in children, will be presented at the 17th International Myopia Conference 2019, held
- Registration Now Open for International Sports Vision Association Annual Conferencehttps://modernod.com/news/registration-now-open-for-international-sports-vision-association-annual-conference/2476869/Registration is now open for Beyond 20/20, the 4th annual International Sports Vision Association (ISVA) conference, February 6-8, 2020, at the Bahia Resort Hotel in San Diego, California. “Sports Vision, the science of helping athletes reach peak levels of performance through t
- Novartis Announces Details of TALON Global Clinical Trial in Wet AMD Comparing Brolucizumab vs Aflibercepthttps://modernod.com/news/novartis-announces-details-of-talon-global-clinical-trial-in-wet-amd-comparing-brolucizumab-vs-aflibercept/2476870/In the phase 3b TALON clinical trial, Novartis announced that the two primary endpoints are superiority for brolucizumab in treatment interval duration and noninferiority in change in visual acuity. Secondary endpoints will examine durability and anatomical outcomes, including retinal fluid resol
- Oxurion Reports Additional Positive Topline Data from Phase 1 With THR-149, a Novel, Potent Plasma Kallikrein Inhibitor for DMEhttps://modernod.com/news/oxurion-reports-additional-positive-topline-data-from-phase-1-with-thr-149-a-novel-potent-plasma-kallikrein-inhibitor-for-dme/2476862/Oxurion reported additional positive topline data from a phase 1 study with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of diabetic macular edema (DME). This phase 1 open-label, multicenter (US), non-randomized trial evaluated the safety of a single intra
- Novartis Announces EU Approval of Lucentis for Preterm Infants With Retinopathy of Prematurity (ROP)https://modernod.com/news/novartis-announces-eu-approval-of-lucentis-for-preterm-infants-with-retinopathy-of-prematurity-rop/2476856/Novartis announced the European approval of Lucentis (ranibizumab) for preterm infants with retinopathy of prematurity (ROP), making it the first and only licensed pharmacological treatment for this indication. The approval is based on the landmark RAINBOW study, showing Lucentis is an eff
- NHS England to Fund Novartis’ Gene Therapy Luxturna for Inherited Retinal Diseasehttps://modernod.com/news/nhs-england-to-fund-novartis-gene-therapy-luxturna-for-inherited-retinal-disease/2476855/NHS England announced Wednesday funding for Novartis’ Luxturna (voretigene neparvovec) after agreeing a deal with the company that will provide access to the gene therapy from January 2020. The one-time treatment gained European Commission approval last year for patients with vision loss du